硝酸益康唑通过抑制PI3K/AKT信号通路逆转乳腺癌细胞对阿霉素的耐药性。
Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.
作者信息
Dong Chao, Chen Yin, Ma Jing, Yang Runxiang, Li Hongjian, Liu Rong, You Dingyun, Luo Chunxiang, Li Heng, Yang Siyuan, Ke Kunbin, Lin Marie Chia-Mi, Chen Ceshi
机构信息
Department of The Second Medical Oncology, The 3rd Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital Kunming, China.
Department of Urology, Changhai Hospital, Navy Medical University (Second Military Medical University) Shanghai, China.
出版信息
Am J Cancer Res. 2020 Jan 1;10(1):263-274. eCollection 2020.
Abstract
Activation of the phosphoinositide 3 kinase (PI3K)/AKT pathway is frequently implicated in resistance to anticancer therapies. PI3K inhibitors can restore sensitivity to standard breast cancer therapies, including endocrine therapy, HER2-targeted agents, and chemotherapy. Our previous research showed that econazole, a novel PI3Ka inhibitor, inhibits the PI3K/AKT pathway and induces apoptosis in lung cancer cells. In this study, econazole showed significant cytotoxic activity against Adriamycin-resistant breast cancer cells and . Additionally, econazole significantly sensitized MDA-MB-231 and MCF-7 cells to Adriamycin via inhibiting the PI3K/AKT pathway. Overexpression of constitutively active AKT1 abolished the function of econazole. The combination of econazole and Adriamycin exerted synergistic inhibitory effects in breast cancer cells and . Taken together, the PI3K inhibitor econazole could effectively overcome Adriamycin resistance and showed synergistic effects with chemotherapy on breast cancer.
摘要
磷酸肌醇3激酶（PI3K）/AKT信号通路的激活常常与抗癌治疗耐药相关。PI3K抑制剂能够恢复对包括内分泌治疗、HER2靶向药物和化疗在内的标准乳腺癌治疗的敏感性。我们之前的研究表明，新型PI3Ka抑制剂益康唑可抑制PI3K/AKT信号通路并诱导肺癌细胞凋亡。在本研究中，益康唑对阿霉素耐药的乳腺癌细胞显示出显著的细胞毒活性。此外，益康唑通过抑制PI3K/AKT信号通路使MDA-MB-231和MCF-7细胞对阿霉素显著敏感。组成型活性AKT1的过表达消除了益康唑的作用。益康唑与阿霉素联合使用对乳腺癌细胞发挥协同抑制作用。综上所述，PI3K抑制剂益康唑可有效克服阿霉素耐药，并与化疗对乳腺癌显示出协同作用。
相似文献
1
Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.硝酸益康唑通过抑制PI3K/AKT信号通路逆转乳腺癌细胞对阿霉素的耐药性。
Am J Cancer Res. 2020 Jan 1;10(1):263-274. eCollection 2020.
2
Erratum: Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway.勘误：硝酸益康唑通过抑制PI3K/AKT信号通路逆转乳腺癌细胞对阿霉素的耐药性。
Am J Cancer Res. 2022 Jul 15;12(7):3486-3490. eCollection 2022.
3
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.克服癌症治疗获得性耐药：聚焦 PI3K/AKT/mTOR 通路。
Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Epub 2013 Feb 3.
4
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.硝酸益康唑抑制肺癌细胞中的 PI3K 活性并促进其凋亡。
Sci Rep. 2017 Dec 21;7(1):17987. doi: 10.1038/s41598-017-18178-0.
5
Baicalein induces apoptosis and autophagy of breast cancer cells via inhibiting PI3K/AKT pathway in vivo and vitro.黄芩素通过在体内和体外抑制PI3K/AKT信号通路诱导乳腺癌细胞凋亡和自噬。
Drug Des Devel Ther. 2018 Nov 16;12:3961-3972. doi: 10.2147/DDDT.S181939. eCollection 2018.
6
Different effects of 4β-hydroxywithanolide E and withaferin A, two withanolides from Solanaceae plants, on the Akt signaling pathway in human breast cancer cells.甾体生物碱 4β-羟基茄次碱 E 和澳洲茄次碱 A 对人乳腺癌细胞 Akt 信号通路的不同影响。
Phytomedicine. 2019 Feb;53:213-222. doi: 10.1016/j.phymed.2018.09.017. Epub 2018 Sep 5.
7
AMR-Me inhibits PI3K/Akt signaling in hormone-dependent MCF-7 breast cancer cells and inactivates NF-κB in hormone-independent MDA-MB-231 cells.AMR-Me抑制激素依赖性MCF-7乳腺癌细胞中的PI3K/Akt信号传导，并使激素非依赖性MDA-MB-231细胞中的NF-κB失活。
Mol Carcinog. 2014 Jul;53(7):578-88. doi: 10.1002/mc.22012. Epub 2013 Mar 8.
8
Inhibitory effects of everolimus in combination with paclitaxel on adriamycin-resistant breast cancer cell line MDA-MB-231.依维莫司联合紫杉醇对阿霉素耐药乳腺癌细胞系MDA-MB-231的抑制作用。
Taiwan J Obstet Gynecol. 2020 Nov;59(6):828-834. doi: 10.1016/j.tjog.2020.09.008.
9
Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells.上调乳腺癌耐药蛋白通过 MCF7 乳腺癌细胞中的 PI3K/Akt 和核因子-κB 信号通路在 HER2 介导的化疗耐药中发挥作用。
Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.
10
Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.靶向 PI3K/mTOR 可克服抗 HER2 治疗的耐药性，而不依赖于 AKT 的反馈激活。
Clin Cancer Res. 2014 Jul 1;20(13):3507-20. doi: 10.1158/1078-0432.CCR-13-2769. Epub 2014 May 30.
引用本文的文献
1
Nociceptive transient receptor potential ankyrin 1 (TRPA1) in sensory neurons are targets of the antifungal drug econazole.感觉神经元中的伤害性瞬时受体电位锚蛋白 1（TRPA1）是抗真菌药物益康唑的作用靶点。
BMC Pharmacol Toxicol. 2024 Aug 21;25(1):53. doi: 10.1186/s40360-024-00779-x.
2
Econazole selectively induces cell death in NF1-homozygous mutant tumor cells.依康唑选择性诱导 NF1 纯合突变肿瘤细胞死亡。
Cell Rep Med. 2023 Dec 19;4(12):101309. doi: 10.1016/j.xcrm.2023.101309. Epub 2023 Dec 11.
3
Characteristics and survival analysis of breast cancer survivors with metachronous double primary cancers: a retrospective cohort study.异时性双原发性癌症乳腺癌幸存者的特征及生存分析：一项回顾性队列研究
Transl Cancer Res. 2023 Apr 28;12(4):939-948. doi: 10.21037/tcr-23-301. Epub 2023 Apr 24.
4
Expression of colorectal neoplasia differentially expressed in anaplastic thyroid carcinoma and its effect on cancer cell proliferation.结直肠癌差异表达基因在间变性甲状腺癌中的表达及其对癌细胞增殖的影响。
Ann Transl Med. 2022 Apr;10(8):473. doi: 10.21037/atm-22-945.
5
The Pathogenic Role of PI3K/AKT Pathway in Cancer Onset and Drug Resistance: An Updated Review.PI3K/AKT信号通路在癌症发生和耐药中的致病作用：最新综述
Cancers (Basel). 2021 Aug 5;13(16):3949. doi: 10.3390/cancers13163949.
6
Identification of significant genes and therapeutic agents for breast cancer by integrated genomics.基于整合基因组学的乳腺癌相关基因和治疗药物鉴定。
Bioengineered. 2021 Dec;12(1):2140-2154. doi: 10.1080/21655979.2021.1931642.
7
Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer.PI3K/AKT/mTOR通路的激活导致乳腺癌耐药。
Front Pharmacol. 2021 Mar 15;12:628690. doi: 10.3389/fphar.2021.628690. eCollection 2021.
8
Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin.大黄素干扰AKT1介导的DNA损伤并降低乳腺癌细胞对多柔比星的耐药性。
Front Oncol. 2021 Feb 9;10:588533. doi: 10.3389/fonc.2020.588533. eCollection 2020.
9
PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers.PI3K/AKT 通路作为关键环节调节癌症的多药耐药性。
Cell Death Dis. 2020 Sep 24;11(9):797. doi: 10.1038/s41419-020-02998-6.
本文引用的文献
1
Ilamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2.伊拉霉素 E 是一种海洋放线菌的天然产物，通过内质网应激-CHOP-Bcl-2 途径部分抑制三阴性乳腺癌。
Int J Biol Sci. 2019 Jun 10;15(8):1723-1732. doi: 10.7150/ijbs.35284. eCollection 2019.
2
A Phase Ib, open-label, dose-finding study of alpelisib in combination with paclitaxel in patients with advanced solid tumors.一项关于阿哌利西布联合紫杉醇治疗晚期实体瘤患者的Ib期开放标签剂量探索性研究。
Oncotarget. 2018 Aug 3;9(60):31709-31718. doi: 10.18632/oncotarget.25854.
3
Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells.硝酸益康唑抑制肺癌细胞中的 PI3K 活性并促进其凋亡。
Sci Rep. 2017 Dec 21;7(1):17987. doi: 10.1038/s41598-017-18178-0.
4
Efficacy of buparlisib in treating breast cancer.布帕利昔布治疗乳腺癌的疗效。
Expert Opin Pharmacother. 2017 Dec;18(18):2007-2016. doi: 10.1080/14656566.2017.1410139. Epub 2017 Dec 1.
5
HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.HOXB4基因敲低通过PI3K/Akt信号通路下调P-糖蛋白、多药耐药相关蛋白1（MRP1）和乳腺癌耐药蛋白（BCRP）的表达，从而逆转人髓系白血病K562/ADM细胞的多药耐药性。
Int J Oncol. 2016 Dec;49(6):2529-2537. doi: 10.3892/ijo.2016.3738. Epub 2016 Oct 18.
6
Effects of PI3K inhibitor NVP-BKM120 on overcoming drug resistance and eliminating cancer stem cells in human breast cancer cells.PI3K抑制剂NVP-BKM120对克服人乳腺癌细胞耐药性及消除癌干细胞的作用
Cell Death Dis. 2015 Dec 17;6(12):e2020. doi: 10.1038/cddis.2015.363.
7
Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.PI3K抑制剂pilaralisib或voxtalisib联合来曲唑用于对非甾体芳香化酶抑制剂难治的激素受体阳性且HER2阴性转移性乳腺癌患者的I/II期剂量递增研究。
Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.
8
PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.PI3K抑制剂联合化疗可增强神经母细胞瘤细胞的体内外凋亡。
Technol Cancer Res Treat. 2016 Oct;15(5):716-22. doi: 10.1177/1533034615597366. Epub 2015 Jul 29.
9
PI3K/Akt inhibition and down-regulation of BCRP re-sensitize MCF7 breast cancer cell line to mitoxantrone chemotherapy.PI3K/Akt抑制及BCRP下调使MCF7乳腺癌细胞系对米托蒽醌化疗重新敏感。
Iran J Basic Med Sci. 2015 May;18(5):472-7.
10
Autophagy facilitates multidrug resistance development through inhibition of apoptosis in breast cancer cells.自噬通过抑制乳腺癌细胞凋亡促进多药耐药性的发展。
Neoplasma. 2015;62(2):199-208. doi: 10.4149/neo_2015_025.
Zotero 插件